{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', \"INVESTIGATOR'S AGREEMENT\", '3', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '4', 'TABLE OF CONTENTS', '8', '1.', 'PROTOCOL SUMMARY', '15', '1.1.', 'Synopsis', '15', '1.2.', 'Schema', '19', '1.3.', 'Schedule of Activities', '20', '2.', 'INTRODUCTION', '26', '2.1.', 'Generalized Myasthenia Gravis', '26', '2.2.', 'Background', '26', '2.2.1.', 'Unmet Medical Need in Patients With Generalized Myasthenia Gravis', '26', '2.2.2.', 'Role of Complement in Myasthenia Gravis', '26', '2.3.', 'Study Rationale', '27', '2.4.', 'Benefit/Risk Assessment', '28', '2.4.1.', 'Identified and Potential Risks', '28', '2.4.1.1.', 'Identified Risk', '28', '2.4.1.2.', 'Potential Risks', '28', '3.', 'OBJECTIVES AND ENDPOINTS', '30', '4.', 'STUDY DESIGN', '31', '4.1.', 'Overall Design', '31', '4.1.1.', 'Screening Period (2 - 4 Weeks Prior to Day 1)', '32', '4.1.2.', 'Randomization', '32', '4.1.3.', 'Randomized Controlled Period (26 Weeks)', '32', '4.1.4.', 'Open-Label Extension Period', '33', '4.2.', 'Standard Protocol Definitions', '33', '4.2.1.', 'Clinical Deterioration', '33', '4.2.2.', 'Unscheduled Visits', '33', '4.2.3.', 'Properly Trained Clinical Evaluator', '33', '4.2.4.', 'Responsibilities for Myasthenia Gravis Assessments', '34', '4.3.', 'Scientific Rationale for Study Design', '34', 'Page 8 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.4.', 'Justification for Dose', '35', '4.5.', 'End of Study Definition', '36', '5.', 'STUDY POPULATION', '37', '5.1.', 'Inclusion Criteria', '37', '5.2.', 'Exclusion Criteria', '38', '5.3.', 'Lifestyle Considerations', '39', '5.4.', 'Screen Failures', '39', '6.', 'STUDY DRUG', '40', '6.1.', 'Study Drugs Administered', '40', '6.2.', 'Preparation/Handling/Storage/Accountability.', '42', '6.2.1.', 'Study Drug Preparation', '42', '6.2.2.', 'Storage', '42', '6.2.3.', 'Packaging and Labeling', '43', '6.2.4.', 'Accountability', '43', '6.2.5.', 'Handling and Disposal', '43', '6.3.', 'Measures to Minimize Bias: Randomization and Blinding', '44', '6.3.1.', 'Randomization', '44', '6.3.2.', 'Blinding', '44', '6.4.', 'Concomitant Therapy', '45', '6.5.', 'Study Drug Compliance', '45', '6.5.1.', 'Allowed Medications', '45', '6.5.1.1.', 'Palliative and Supportive Care', '45', '6.5.1.2.', 'Cholinesterase Inhibitors', '45', '6.5.1.3.', 'Immunosuppressive Agents', '46', '6.5.1.4.', 'Plasma Exchange/Plasmapheresis/Intravenous Immunoglobulin', '46', '6.5.1.5.', 'Disallowed Medications and Therapies', '49', '6.5.2.', 'Rescue Therapy', '49', '6.6.', 'Intervention After the End of the Study', '49', '7.', 'DISCONTINUATION OF STUDY INTERVENTION AND PATIENT', 'DISCONTINUATION/WITHDRAWAL', '50', '7.1.', 'Discontinuation of Study Intervention', '50', '7.2.', 'Lost to Follow Up', '50', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', '52', 'Page 9 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}